Researchers blocking a single protein called PTP1B restored memory in mice and accelerated the brain's removal of toxic plaque associated with Alzheimer's disease. The protein, which sits at the intersection of neurodegeneration and metabolic disease, also drives diabetes and obesity. These connections suggest a unified treatment target could address multiple conditions simultaneously.
The team found that inhibiting PTP1B activated microglia, the brain's immune cells responsible for clearing amyloid plaques. This dual effect makes the protein particularly attractive for drug development. Rather than treating Alzheimer's in isolation, blocking PTP1B could simultaneously reduce metabolic risk factors that increase dementia susceptibility.
The next phase involves testing this approach in human subjects. Researchers must determine whether blocking PTP1B in people produces the same memory improvements observed in mice, and whether it carries side effects. They will also explore whether combining this strategy with existing Alzheimer's treatments produces better outcomes.
The discovery reframes how scientists think about dementia prevention. Instead of targeting brain pathology alone, interventions addressing metabolic health throughout life could prevent the conditions that enable Alzheimer's to develop.